The Brains Behind SGLT2 Inhibition

Article Endocrinology & Metabolism

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Stephanie Kullmann et al.

Summary: SGLT2 inhibitors could be a pharmacological approach to reverse brain insulin resistance and improve overall metabolism in prediabetic individuals.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

Empagliflozin Improves Insulin Sensitivity of the Hypothalamus in Humans With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial

Stephanie Kullmann et al.

Summary: Insulin action in the human brain plays an important role in regulating food intake and whole-body insulin sensitivity. This study found that treatment with empagliflozin for 8 weeks can restore hypothalamic insulin sensitivity in individuals with prediabetes, suggesting that SGLT2 inhibition may be a potential pharmacological approach to reverse brain insulin resistance and improve overall metabolism.

DIABETES CARE (2022)

Add to Collection

Article Endocrinology & Metabolism

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

Rosalie A. Scholtes et al.

Summary: Dapagliflozin reduced blood pressure without significant changes in urinary sodium excretion during standardized sodium intake, suggesting factors other than natriuresis and volume changes may contribute to its blood pressure-lowering effects.

DIABETES CARE (2021)

Add to Collection

Review Medicine, General & Internal

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Suetonia C. Palmer et al.

Summary: This network meta-analysis evaluated the effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk levels. The study found that both classes of drugs lowered mortality and improved cardiovascular outcomes, with notable differences in effects between the two agents. Additional benefits and adverse effects varied across different risk groups.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Endocrinology & Metabolism